﻿<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Explor Med</journal-id>
<journal-id journal-id-type="publisher-id">EM</journal-id>
<journal-title-group>
<journal-title>Exploration of Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2692-3106</issn>
<publisher>
<publisher-name>Open Exploration Publishing</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.37349/emed.2026.1001417</article-id>
<article-id pub-id-type="manuscript">1001417</article-id>
<article-categories>
<subj-group>
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical and health system factors associated with antiretroviral therapy adherence among people living with HIV and AIDS: cross-sectional survey insights from three ART facilities in Tamale, Ghana</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-5611-4066</contrib-id>
<name>
<surname>Abdul-Samed</surname>
<given-names>Faisal Gunu</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7119-8590</contrib-id>
<name>
<surname>Haruna</surname>
<given-names>Umar</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alimatu</surname>
<given-names>Abdulai</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5654-2445</contrib-id>
<name>
<surname>Aninanya</surname>
<given-names>Gifty Apiung</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="editor">
<name>
<surname>Lu</surname>
<given-names>Hongzhou</given-names>
</name>
<role>Academic Editor</role>
<aff>Shenzhen Third People’s Hospital, National Clinical Research Center for Infectious Diseases, China</aff>
</contrib>
</contrib-group>
<aff id="I1">
<sup>1</sup>Department of Global Health, School of Public Health, University for Development Studies, Tamale NT-0272-8036, Ghana</aff>
<aff id="I2">
<sup>2</sup>Department of Intensive Care Unit, Tamale Teaching Hospital, Tamale NT-0101-4936<bold>,</bold> Ghana</aff>
<aff id="I3">
<sup>3</sup>Department of Social and Behavioral Change, School of Public Health, University for Development Studies, Tamale NT-0272-8036, Ghana</aff>
<aff id="I4">
<sup>4</sup>Department of Maternal and Child Health, Tamale Technical University Hospital, Tamale NS-029-9746, Ghana</aff>
<author-notes>
<corresp id="cor1">
<bold>
<sup>*</sup>Correspondence:</bold> Faisal Gunu Abdul-Samed, Department of Global Health, School of Public Health, University for Development Studies, Tamale NT-0272-8036, Ghana; Department of Intensive Care Unit, Tamale Teaching Hospital, Tamale NT-0101-4936, Ghana. <email>faisala.samed@gmail.com</email>; <email>faisalab2273@uds.edu.gh</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2026</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>07</month>
<year>2026</year>
</pub-date>
<volume>7</volume>
<elocation-id>1001417</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>06</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2026.</copyright-statement>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Aim:</title>
<p id="absp-1">Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) have attained a manageable chronic status as more infected people experience increases in their life quality and expectancy. Health system factors affect adherence to Antiretroviral Therapy (ART) among persons living with HIV (PLHIV). Nonetheless, literature on health-system factors and ART adherence among PLHIV is sparse. This study therefore aimed to elucidate clinical and health system factors associated with ART adherence among PLHIV in Tamale Metropolis.</p>
</sec>
<sec>
<title>Methods:</title>
<p id="absp-2">We conducted a facility-based cross-sectional survey of 418 PLHIV in the Tamale Metropolis, selected by convenience sampling from three major ART centres. Each factor associated with ART adherence, considered statistically significant at a <italic>p</italic>-value of &lt; 0.05 with a 95% confidence interval, was analysed using both binary and multivariate logistic regression. Adherence was assessed by self-report of missed doses in the past 30 days, categorised as good (≥ 95% of prescribed doses taken) or poor (&lt; 95% of prescribed doses taken).</p>
</sec>
<sec>
<title>Results:</title>
<p id="absp-3">The overall ART adherence rate was 93.1% (95% CI: 90.3%–95.2%). Clinical and health system factors significantly associated with higher adherence included the absence of post-pill fatigue (AOR = 0.09; 95% CI: 0.02–0.37), absence of complaints regarding pill size (AOR = 3.71; 95% CI: 1.23–11.18), lower cost of accessing therapy (AOR = 0.27; 95% CI: 0.10–0.73), uninterrupted ART supply (AOR = 7.76; 95% CI: 1.02–59.30), and strong social support systems (AOR = 6.62; 95% CI: 1.18–37.21).</p>
</sec>
<sec>
<title>Conclusions:</title>
<p id="absp-4">An adherence rate of 93% was obtained which falls short of the 95% global benchmark. Clinical factors promoting adherence included the absence of fatigue and concerns related to pill size, while health system-related factors promoting adherence included reduced cost of access, consistent ART supply, and good social support. The Ghana AIDS Commission and its implementing partners are urged to strengthen community-based social support networks, expand ART distribution points, and develop targeted educational initiatives to improve therapy adherence and contribute to achieving epidemic control. Limitations of this study include the use of self-reported adherence (potential recall and social desirability bias) and the cross-sectional design, which precludes causal inference.</p>
</sec>
</abstract>
<kwd-group>
<kwd>adherence</kwd>
<kwd>antiretroviral therapy</kwd>
<kwd>HIV&amp;AIDS</kwd>
<kwd>Ghana</kwd>
<kwd>Tamale Metropolis</kwd>
<kwd>health systems</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p id="p-1">It has been 30 years to date, after the 1996 introduction of the Highly Active Antiretroviral Therapy (HAART), Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) have become manageable chronic conditions as more infected people experience increases in the quality and expectancy of their lives [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. However, HIV and AIDS remain a paramount global public health challenge, with a worldwide imperative to eradicate AIDS and accelerate the HIV response by 2030 [<xref ref-type="bibr" rid="B3">3</xref>]. In 2021, the incidence of newly diagnosed HIV infections was 1.5 million, with 650,000 deaths attributed to AIDS, and an approximate total of 38.4 million persons living with HIV (PLHIV, 54% women and girls). Of these, 28.7 million (75% of PLHIV) could access ART. Despite efforts to curb novel infections and fatalities, Sub-Saharan Africa maintains the highest HIV prevalence globally, with approximately one in every twenty-five adults infected, constituting over two-thirds of all PLHIV worldwide. Moreover, the region is responsible for 45% of new HIV infections and half of all AIDS-related deaths globally [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>].</p>
<p id="p-2">Adherence is defined as the degree to which a patient follows the instructions of a healthcare professional regarding prescribed medications [<xref ref-type="bibr" rid="B6">6</xref>]. Understanding the factors affecting PLHIV’s effective and regular adherence to ART is crucial to addressing adherence which falls short of the 95% global benchmark adherence. Notable clinical factors include the use of traditional and herbal medicine, doubts concerning the benefits of ART, side effects, and the burden of pill consumption [<xref ref-type="bibr" rid="B7">7</xref>–<xref ref-type="bibr" rid="B10">10</xref>]. Health systems factors include discontentment with healthcare facilities and staff in particular, extended wait times, stockouts/shortages, distance, unforeseen facility charges, out-of-pocket expenses for medications and transportation to services, expenses of forgoing daily income-generating activities [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B11">11</xref>]. Studies conducted in Ghana that incorporated health system determinants of ART adherence have reported adherence rates of 51.2%, 44.6%, and 73%, respectively. Key factors associated with adherence that fall short of the 95% global benchmark include complex dosing regimens (i.e., more than one dose per day), the presence of treatment-related side effects, lack of regular reminders from healthcare providers, and long travel distances to ART centers, specifically distances of 51 kilometers or more [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B12">12</xref>].</p>
<p id="p-3">Ghana currently implements a triple therapy regimen for PLHIV, including either one nucleotide reverse transcriptase inhibitor (NtRTI), one nucleoside reverse transcriptase inhibitor (NRTI), and one integrase strand transfer inhibitor (INSTI) (primarily dolutegravir) as preferred first-line treatment for adults, or one NtRTI, one NRTIs, and one non-nucleoside reverse transcriptase inhibitor (NNRTI) (primarily efavirenz) as an alternative first-line option [<xref ref-type="bibr" rid="B13">13</xref>]. Ghana has an estimated 334,713 PLHIV as of 2018 with only 34% on ART, the country’s HIV prevalence of 1.7% suggests a moderate HIV burden compared to several African nations. AIDS-related mortality in Ghana accounts for 14,181 deaths annually [<xref ref-type="bibr" rid="B14">14</xref>]. In Ghana’s Northern region, HIV prevalence is 0.6%, affecting around 6,941 PLHIV. Tamale Metropolis contributes significantly, constituting 30% of the region’s prevalence and achieving 88% ART coverage [<xref ref-type="bibr" rid="B15">15</xref>]. Studies conducted in Northern Ghana have examined ART adherence, but they have focused predominantly on individual or socio-cultural factors [<xref ref-type="bibr" rid="B16">16</xref>]. To our knowledge, no study in this region has quantitatively examined both clinical factors and health system factors within a single multivariable framework. This gap is significant because health system determinants are often modifiable through policy and programmatic interventions, yet their relative contribution to adherence in Northern Ghana remains unquantified.</p>
<p id="p-4">This study thus aimed to examine the clinical and health system challenges that PLHIV encounter in maintaining consistent adherence to their treatment regimen in the Tamale Metropolis. Objectives were to: (i) identify ART adherence rate and reported clinical and health system challenges; (ii) analyse associations between clinical and health system factors and ART adherence; and (iii) identify and prioritise actionable recommendations for healthcare providers, policymakers, and community organisations based on the strength of associations between modifiable factors and adherence. To our knowledge, no previous study in Northern Ghana has quantitatively examined both clinical factors and health system factors within a single multivariable framework.</p>
</sec>
<sec id="s2">
<title>Materials and methods</title>
<sec id="t2-1">
<title>Study design and setting</title>
<p id="p-5">We conducted a facility-based cross-sectional survey in three ART centres within Tamale Metropolis, namely Tamale Teaching Hospital (TTH), Tamale West Hospital (TWH), and Tamale Central Hospital (TCH). These facilities function as crucial referral points for the five northern regions of Ghana and neighbouring countries such as Togo, Ivory Coast, and Burkina Faso [<xref ref-type="bibr" rid="B17">17</xref>].</p>
</sec>
<sec id="t2-2">
<title>Study population</title>
<p id="p-6">Eligibility criteria included PLHIV, aged 18 years or more, receiving ART at TTH, TWH, or TCH for at least six months, consenting to participate, and being in good physical/mental health, as determined through objective observation/interaction and a basic physical assessment. PLHIV experiencing critical clinical conditions during data collection or with speech or hearing impairments were excluded.</p>
</sec>
<sec id="t2-3">
<title>Sampling size determination</title>
<p id="p-7">To estimate the desired effect and ensure the study was adequately powered, we calculated the sample size using the Cochran formula [<xref ref-type="bibr" rid="B18">18</xref>]:</p>
<p id="p-8">
<disp-formula id="eq1">
<label></label>
<mml:math id="m384c0">
<mml:mi>n</mml:mi>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>z</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo>×</mml:mo>
<mml:mi>p</mml:mi>
<mml:mi>q</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:mfrac>
</mml:math>
</disp-formula>
</p>
<p id="p-9">where <italic>z</italic> = reliability coefficient, <italic>d</italic> = margin of error, <italic>p</italic> = approximate percentage, <italic>q</italic> = 1 – <italic>p</italic>.</p>
<p id="p-10">This calculation accounted for a reliability coefficient of 1.96, a 95% confidence interval (95% CI), and a margin of error of 5%, assuming an approximate percentage of 44.6% for PLHIV [<xref ref-type="bibr" rid="B8">8</xref>]. The estimated sample size was calculated using the following approach:</p>
<p id="p-11">
<disp-formula id="eq2">
<label></label>
<mml:math id="m8fe37">
<mml:mi>n</mml:mi>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mn>1.96</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo>×</mml:mo>
<mml:mn>0.446</mml:mn>
<mml:mo>×</mml:mo>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>-</mml:mo>
<mml:mn>0.446</mml:mn>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mn>0.05</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:mfrac>
<mml:mo>=</mml:mo>
<mml:mn>379.68</mml:mn>
</mml:math>
</disp-formula>
</p>
<p id="p-12">The resulting sample size was 380 participants. To address potential non-response, a 10% adjustment was applied (10% of 380 = 38), increasing the required sample size to 418 participants.</p>
</sec>
<sec id="t2-4">
<title>Sampling techniques and procedures</title>
<p id="p-13">Three ART facilities (TTH, TCH and TWH) were purposively selected because they are the major referral hospitals within the Tamale Metropolis. Participants were then allocated to each facility using proportional allocation based on the formula: <italic>n</italic><sub>i</sub> = (<italic>N</italic><sub>i</sub>/<italic>N</italic>) × <italic>n</italic>, where <italic>n</italic><sub>i</sub> is the number of participants sampled from facility <italic>I</italic>, <italic>N</italic><sub>i</sub> is the total number of eligible individuals at facility <italic>I</italic>, <italic>N</italic> is the total eligible population across all three sites, and <italic>n</italic> is the total sample size. This approach yielded 200 participants from TTH, 118 participants from TCH and 100 participants from TWH. Within each facility, convenience sampling was then employed to recruit participants who met the eligibility criteria. If a chosen individual declined to participate, another eligible participant was recruited in their place to ensure the target sample size was maintained.</p>
</sec>
<sec id="t2-5">
<title>Data collection</title>
<p id="p-14">We adapted a questionnaire from various studies [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B19">19</xref>–<xref ref-type="bibr" rid="B23">23</xref>] and pre-tested with a convenience sample of 3 PLHIV at the TCH to ensure clarity and relevance. Topics included ART adherence (i.e., missed none, &lt; 3 doses, 3–12 doses, over 12 doses), socio-demographics, clinical and health system factors with scaled responses (i.e., “Strongly Agree,” “Agree,” “Disagree,” “Strongly Disagree”).</p>
<p id="p-15">Structured interviews were conducted by seven trained enumerators using a standardized approach. Each interview lasted a maximum of 45 minutes and took place between 27/11/23 and 20/02/24. To ensure consistency and minimize interviewer-related variability, all enumerators received the same training and followed a standard interview protocol. Enumerators were proficient in both English and Dagbani and translated questions as needed for participants who preferred Dagbani. Interviews were conducted in private rooms within each facility to guarantee privacy. Written informed consent was obtained from all participants, and confidentiality was maintained by assigning each participant a unique identification code; no personally identifiable information was collected. Data reliability and completeness were checked daily, and data were entered and coded using Microsoft Excel.</p>
</sec>
<sec id="t2-6">
<title>Analysis</title>
<p id="p-16">Data were transferred to SPSS version 21 for analysis. The primary outcome variable was self-reported ART adherence, with a binary categorisation of ‘good adherence’ if participants reported taking at least 95% (i.e., missed none or &lt; 3 doses) of their prescribed medication in the past 30 days or ‘poor adherence’ if they reported taking less than 95% (i.e., missing 3+ doses) of their prescribed medication in the past 30 days.</p>
<p id="p-17">Independent variables were clinical or health system-related. These were recoded to facilitate binary logistic regression, with “Strongly Agree” and “Agree” taken as Agree, while “Strongly Disagree” and “Disagree” taken as Disagree. Descriptive statistics, including frequencies and percentages, were calculated for all variables to present a comprehensive summary of the dataset. To identify factors significantly associated with ART adherence, bivariate logistic regression was initially conducted. Variables achieving a significance level of 0.05 in the bivariate analysis were subsequently included in the multivariable logistic regression model to control for potential confounding factors. The variables included in the multivariable model were: fatigue, too many pills, pill odour, auditory hallucination, pill size, cost of accessing ART, social support, interrupted ART supply and cost of treating comorbidities. These variables were selected based on their significance in the bivariate analysis.</p>
<p id="p-18">To ensure the validity of the responses related to variables influencing ART adherence, a pre-assessment of the internal consistency of the survey instrument was conducted using Cronbach’s Alpha analysis. This method assessed the reliability of participants’ responses across the 31 survey items. A Cronbach’s Alpha coefficient of 0.8 was obtained, demonstrating good internal consistency. This step, conducted before analyzing the data, confirmed the reliability of the instrument in capturing meaningful responses about ART adherence.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<sec id="t3-1">
<title>Participant characteristics</title>
<p id="p-19">
<xref ref-type="table" rid="t1">Table 1</xref> highlights the demographic profile of the 418 PLHIV surveyed, showing a predominance of females (73.2%; 95% CI: 68.7%–77.3%). The majority were between the ages of 30–49 years (56.5%; 95% CI: 51.7%–61.1%), married or cohabiting (64.4%; 95% CI: 59.5%–68.4%), Muslim (71.5%; 95% CI: 67.0%–75.7%), and of Dagomba ethnicity (64.6%; 95% CI: 59.9%–69.1%), reflecting the local socio-cultural landscape. Educational attainment was low, with about one-third (35.4%; 95% CI: 30.9%–40.1%) having no formal education, whilst the majority (73%; 95% CI: 68.5%–77.2%) lived in urban areas.</p>
<table-wrap id="t1">
<label>Table 1</label>
<caption>
<p id="t1-p-1">
<bold>Demographic characteristics of PLHIV on ART.</bold>
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>
<bold>Variable</bold>
</th>
<th>
<bold>Tamale Central Hospital</bold>
<break />
<bold>(<italic>n</italic> = 118)</bold>
</th>
<th>
<bold>Tamale West Hospital</bold>
<break />
<bold>(<italic>n</italic> = 100)</bold>
</th>
<th>
<bold>Tamale Teaching Hospital</bold>
<break />
<bold>(<italic>n</italic> = 200)</bold>
</th>
<th>
<bold>Total</bold>
<break />
<bold>(<italic>N</italic> = 418)</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">
<bold>Age groups</bold>
</td>
</tr>
<tr>
<td>18–29</td>
<td>25 (21.2%)</td>
<td>24 (24.0%)</td>
<td>51 (25.5%)</td>
<td>100 (23.9%)</td>
</tr>
<tr>
<td>30–49</td>
<td>72 (61.0%)</td>
<td>61 (61.0%)</td>
<td>103 (51.5%)</td>
<td>236 (56.5%)</td>
</tr>
<tr>
<td>≥ 50</td>
<td>21 (17.8%)</td>
<td>15 (15.0%)</td>
<td>46 (23.0%)</td>
<td>82 (19.6%)</td>
</tr>
<tr>
<td colspan="5">
<bold>Gender</bold>
</td>
</tr>
<tr>
<td>Male</td>
<td>28 (23.7%)</td>
<td>21 (21.0%)</td>
<td>63 (31.5%)</td>
<td>112 (26.8%)</td>
</tr>
<tr>
<td>Female</td>
<td>90 (76.3%)</td>
<td>79 (79.0%)</td>
<td>137 (68.5%)</td>
<td>306 (73.2%)</td>
</tr>
<tr>
<td colspan="5">
<bold>Marital status</bold>
</td>
</tr>
<tr>
<td>Married/cohabiting</td>
<td>72 (61.0%)</td>
<td>58 (58.0%)</td>
<td>139 (69.5%)</td>
<td>269 (64.4%)</td>
</tr>
<tr>
<td>Single</td>
<td>25 (21.2%)</td>
<td>32 (32.0%)</td>
<td>38 (19.0%)</td>
<td>95 (22.7%)</td>
</tr>
<tr>
<td>Widowed/divorced</td>
<td>21 (17.8%)</td>
<td>10 (10.0%)</td>
<td>23 (11.5%)</td>
<td>54 (12.9%)</td>
</tr>
<tr>
<td colspan="5">
<bold>Religion</bold>
</td>
</tr>
<tr>
<td>Islam</td>
<td>85 (72.0%)</td>
<td>79 (79.0%)</td>
<td>135 (67.5%)</td>
<td>299 (71.5%)</td>
</tr>
<tr>
<td>Christianity</td>
<td>33 (28.0%)</td>
<td>21 (21.0%)</td>
<td>65 (32.5%)</td>
<td>119 (28.5%)</td>
</tr>
<tr>
<td colspan="5">
<bold>Education Level</bold>
</td>
</tr>
<tr>
<td>No Formal education</td>
<td>43 (36.4%)</td>
<td>40 (40.0%)</td>
<td>65 (32.5%)</td>
<td>148 (35.4%)</td>
</tr>
<tr>
<td>Formal education</td>
<td>75 (63.6%)</td>
<td>60 (60.0%)</td>
<td>135 (67.5%)</td>
<td>270 (64.6%)</td>
</tr>
<tr>
<td colspan="5">
<bold>Settlement type</bold>
</td>
</tr>
<tr>
<td>Urban</td>
<td>79 (66.9%)</td>
<td>86 (86.0%)</td>
<td>140 (70.0%)</td>
<td>305 (73.0%)</td>
</tr>
<tr>
<td>Rural/subrural</td>
<td>39 (33.1%)</td>
<td>14 (14.0%)</td>
<td>60 (30.0%)</td>
<td>113 (27.0%)</td>
</tr>
<tr>
<td colspan="5">
<bold>Tribe</bold>
</td>
</tr>
<tr>
<td>Dagomba</td>
<td>80 (67.8%)</td>
<td>70 (70.0%)</td>
<td>120 (60.0%)</td>
<td>270 (64.6%)</td>
</tr>
<tr>
<td>Mamprusi</td>
<td>10 (8.5%)</td>
<td>3 (3.0%)</td>
<td>21 (10.5%)</td>
<td>34 (8.1%)</td>
</tr>
<tr>
<td>Others*</td>
<td>28 (23.7%)</td>
<td>27 (27.0%)</td>
<td>59 (29.5%)</td>
<td>114 (27.3%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p id="t1-fn-1">Others*: Mossi, Gonja, Frafra, Builsa, Waala, Kasina, Ga, Dagarti, Fante, Ashanti, Ewe, Hausa, Bimoba, Zabarma. Data were collected from three hospitals in the Tamale Metropolis (Ghana): Tamale Teaching Hospital, Tamale Central Hospital, and Tamale West Hospital. The study period was from November 2023 to February 2024.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="t3-2">
<title>ART adherence</title>
<p id="p-20">
<xref ref-type="table" rid="t2">Table 2</xref> shows that among the 418 PLHIV surveyed, 93.1% (95% CI: 90.3%–95.2%) demonstrated good adherence (defined as ≥ 95% of prescribed doses taken in the past 30 days). The highest adherence was recorded at TTH (95.5%), compared to TWH (89%) and TCH (92.4%).</p>
<table-wrap id="t2">
<label>Table 2</label>
<caption>
<p id="t2-p-1">
<bold>ART adherence rates.</bold>
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>
<bold>Facility</bold>
</th>
<th>
<bold>Good adherence</bold>
</th>
<th>
<bold>Poor adherence</bold>
</th>
<th>
<bold>Total</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tamale Central Hospital</td>
<td>109 (92.4%)</td>
<td>9 (7.6%)</td>
<td>118</td>
</tr>
<tr>
<td>Tamale West Hospital</td>
<td>89 (89.0%)</td>
<td>11 (11.0%)</td>
<td>100</td>
</tr>
<tr>
<td>Tamale Teaching Hospital</td>
<td>191 (95.5%)</td>
<td>9 (4.5%)</td>
<td>200</td>
</tr>
<tr>
<td>
<bold>Overall</bold>
</td>
<td>389 (93.1%)</td>
<td>29 (6.9%)</td>
<td>418</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p id="t2-fn-1">Data were collected from three hospitals in the Tamale Metropolis (Ghana): Tamale Teaching Hospital, Tamale Central Hospital, and Tamale West Hospital.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="t3-3">
<title>Potential clinical factors affecting ART adherence</title>
<p id="p-21">
<xref ref-type="table" rid="t3">Table 3</xref> shows that while 69% (95% CI: 64.6%–73.4%) of participants expressed preference for injectable ART, this finding does not directly predict adherence and requires further investigation. Most (57.9%; 95% CI: 53.3%–62.6%) also reported adhering to their ART regimen despite experiencing side effects.</p>
<table-wrap id="t3">
<label>Table 3</label>
<caption>
<p id="t3-p-1">
<bold>Medication-related factors affecting ART adherence.</bold>
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>
<bold>Statement</bold>
</th>
<th>
<bold>Frequency (<italic>n</italic>)</bold>
</th>
<th>
<bold>Percentage (%)</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">
<bold>I take too many pills.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>49</td>
<td>11.7</td>
</tr>
<tr>
<td>Disagree</td>
<td>369</td>
<td>88.3</td>
</tr>
<tr>
<td colspan="3">
<bold>The pills are too big.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>163</td>
<td>39.0</td>
</tr>
<tr>
<td>Disagree</td>
<td>255</td>
<td>61.0</td>
</tr>
<tr>
<td colspan="3">
<bold>The smell of the pills puts me off.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>30</td>
<td>7.2</td>
</tr>
<tr>
<td>Disagree</td>
<td>388</td>
<td>92.8</td>
</tr>
<tr>
<td colspan="3">
<bold>I would prefer an injection instead of pills.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>290</td>
<td>69.4</td>
</tr>
<tr>
<td>Disagree</td>
<td>128</td>
<td>30.6</td>
</tr>
<tr>
<td colspan="3">
<bold>My energy is reduced/I feel fatigued when I take my ARVs.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>33</td>
<td>7.9</td>
</tr>
<tr>
<td>Disagree</td>
<td>385</td>
<td>92.1</td>
</tr>
<tr>
<td colspan="3">
<bold>I feel severe headaches when I take my medications.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>21</td>
<td>5.0</td>
</tr>
<tr>
<td>Disagree</td>
<td>397</td>
<td>95.0</td>
</tr>
<tr>
<td colspan="3">
<bold>When I take my medication, I experience preferences for certain food types.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>64</td>
<td>15.3</td>
</tr>
<tr>
<td>Disagree</td>
<td>354</td>
<td>84.7</td>
</tr>
<tr>
<td colspan="3">
<bold>Taking my ARVs makes me feel sick.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>23</td>
<td>5.5</td>
</tr>
<tr>
<td>Disagree</td>
<td>395</td>
<td>94.5</td>
</tr>
<tr>
<td colspan="3">
<bold>I hear voices when I take my ARVs.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>14</td>
<td>3.3</td>
</tr>
<tr>
<td>Disagree</td>
<td>404</td>
<td>96.7</td>
</tr>
<tr>
<td colspan="3">
<bold>I am faced with hunger and lack of food because ARVs make me have an increased appetite.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>180</td>
<td>43.1</td>
</tr>
<tr>
<td>Disagree</td>
<td>238</td>
<td>56.9</td>
</tr>
<tr>
<td colspan="3">
<bold>I lose my appetite when I take ARVs.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>21</td>
<td>5.0</td>
</tr>
<tr>
<td>Disagree</td>
<td>397</td>
<td>95.0</td>
</tr>
<tr>
<td colspan="3">
<bold>Taking ARVs has caused me to have lipodystrophy.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>13</td>
<td>3.1</td>
</tr>
<tr>
<td>Disagree</td>
<td>405</td>
<td>96.9</td>
</tr>
<tr>
<td colspan="3">
<bold>I experience nausea/vomiting when I take my ARVs.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>42</td>
<td>10.0</td>
</tr>
<tr>
<td>Disagree</td>
<td>376</td>
<td>90.0</td>
</tr>
<tr>
<td colspan="3">
<bold>I get diarrhoea when I take my ARVs.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>22</td>
<td>5.3</td>
</tr>
<tr>
<td>Disagree</td>
<td>396</td>
<td>94.7</td>
</tr>
<tr>
<td colspan="3">
<bold>I have trouble sleeping when I take my ARVs.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>29</td>
<td>6.9</td>
</tr>
<tr>
<td>Disagree</td>
<td>389</td>
<td>93.1</td>
</tr>
<tr>
<td colspan="3">
<bold>I feel numbness in my hands and legs when I take my ARVs.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>82</td>
<td>19.6</td>
</tr>
<tr>
<td>Disagree</td>
<td>336</td>
<td>80.4</td>
</tr>
<tr>
<td colspan="3">
<bold>I get rash or hypersensitivity when I take my ARVs.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>25</td>
<td>6.0</td>
</tr>
<tr>
<td>Disagree</td>
<td>393</td>
<td>94.0</td>
</tr>
<tr>
<td colspan="3">
<bold>I experience signs and symptoms of anaemia.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>19</td>
<td>4.5</td>
</tr>
<tr>
<td>Disagree</td>
<td>399</td>
<td>95.5</td>
</tr>
<tr>
<td colspan="3">
<bold>The duration and number of times I take my medications affect my treatment adherence.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>44</td>
<td>10.5</td>
</tr>
<tr>
<td>Disagree</td>
<td>374</td>
<td>89.5</td>
</tr>
<tr>
<td colspan="3">
<bold>I adhere to ART despite side effects.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>242</td>
<td>57.9</td>
</tr>
<tr>
<td>Disagree</td>
<td>176</td>
<td>42.1</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p id="t3-fn-1">Responses were binary (Agree/Disagree). ARV: antiretroviral</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="t3-4">
<title>Potential health system factors affecting ART adherence</title>
<p id="p-22">
<xref ref-type="table" rid="t4">Table 4</xref> shows that most participants reported health system factors positively. For example, 91% (95% CI: 87.8%–93.4%) reported favourable health-worker influence, 95% (95% CI: 92.5%–96.8%) reported that health workers emphasized the importance of medication adherence, and 70% (95% CI: 65.5%–74.2%) received refill reminders. A little over 96% (95% CI: 92.5%–96.8%) reported not experiencing any harsh treatment, discrimination, or abuse at healthcare facilities. Most indicated ART services were always available and accessible (98%; 95% CI: 96.1%–99.1%), were confident in facility confidentiality practices (90.4%), and experienced financial (16.3%) and geographical (35.4%) barriers. Notably, only 22% reported receiving social support from NGOs, welfare units, or volunteers. The highest negative response was 55%, who indicated that increasing patient numbers made it more crowded to access ART at their facility, hence impacting their adherence to therapy.</p>
<table-wrap id="t4">
<label>Table 4</label>
<caption>
<p id="t4-p-1">
<bold>Health system factors affecting ART adherence.</bold>
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>
<bold>Statement</bold>
</th>
<th>
<bold>Frequency (<italic>n</italic>)</bold>
</th>
<th>
<bold>Percentage (%)</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">
<bold>I was shouted at/treated harshly by healthcare providers.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>18</td>
<td>4.3</td>
</tr>
<tr>
<td>Disagree</td>
<td>400</td>
<td>95.7</td>
</tr>
<tr>
<td colspan="3">
<bold>Health workers took me through the importance of taking my medications.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>395</td>
<td>94.5</td>
</tr>
<tr>
<td>Disagree</td>
<td>23</td>
<td>5.5</td>
</tr>
<tr>
<td colspan="3">
<bold>I have a cordial relationship with my healthcare providers.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>382</td>
<td>91.4</td>
</tr>
<tr>
<td>Disagree</td>
<td>36</td>
<td>8.6</td>
</tr>
<tr>
<td colspan="3">
<bold>I experience discrimination and abuse in the healthcare unit.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>22</td>
<td>5.3</td>
</tr>
<tr>
<td>Disagree</td>
<td>396</td>
<td>94.7</td>
</tr>
<tr>
<td colspan="3">
<bold>I face high financial costs when accessing and receiving ART (e.g., transport, cost of drugs).</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>68</td>
<td>16.3</td>
</tr>
<tr>
<td>Disagree</td>
<td>350</td>
<td>83.7</td>
</tr>
<tr>
<td colspan="3">
<bold>Interrupted ART supply from healthcare provider (e.g., due to a shortage of drugs and other commodities).</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>34</td>
<td>8.1</td>
</tr>
<tr>
<td>Disagree</td>
<td>384</td>
<td>91.9</td>
</tr>
<tr>
<td colspan="3">
<bold>It takes lots of time for a refill of my medications (long waiting time).</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>26</td>
<td>6.2</td>
</tr>
<tr>
<td>Disagree</td>
<td>392</td>
<td>93.8</td>
</tr>
<tr>
<td colspan="3">
<bold>I lose my income on ART therapy including treating underlying diseases/infections.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>12</td>
<td>2.9</td>
</tr>
<tr>
<td>Disagree</td>
<td>406</td>
<td>97.1</td>
</tr>
<tr>
<td colspan="3">
<bold>The distance from where I stay to the ART centre influences my adherence.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>148</td>
<td>35.4</td>
</tr>
<tr>
<td>Disagree</td>
<td>270</td>
<td>64.6</td>
</tr>
<tr>
<td colspan="3">
<bold>I get reminders from health workers for a refill (positive patient-provider partnership).</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>292</td>
<td>69.9</td>
</tr>
<tr>
<td>Disagree</td>
<td>126</td>
<td>30.1</td>
</tr>
<tr>
<td colspan="3">
<bold>The ART services are always available and easily accessible.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>409</td>
<td>97.8</td>
</tr>
<tr>
<td>Disagree</td>
<td>9</td>
<td>2.2</td>
</tr>
<tr>
<td colspan="3">
<bold>I receive social support (e.g., from the welfare unit, government, NGO, volunteers).</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>91</td>
<td>21.8</td>
</tr>
<tr>
<td>Disagree</td>
<td>327</td>
<td>78.2</td>
</tr>
<tr>
<td colspan="3">
<bold>There is a lack of confidentiality/respect for privacy at the facility.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>40</td>
<td>9.6</td>
</tr>
<tr>
<td>Disagree</td>
<td>378</td>
<td>90.4</td>
</tr>
<tr>
<td colspan="3">
<bold>The number of people accessing ARVs is always increasing at this hospital.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>230</td>
<td>55</td>
</tr>
<tr>
<td>Disagree</td>
<td>188</td>
<td>45</td>
</tr>
<tr>
<td colspan="3">
<bold>Health workers are very slow and not organized because when you come, no matter how early, you will still leave late.</bold>
</td>
</tr>
<tr>
<td>Agree</td>
<td>28</td>
<td>6.7</td>
</tr>
<tr>
<td>Disagree</td>
<td>390</td>
<td>93.3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p id="t4-fn-1">Responses were binary (Agree/Disagree). ARV: antiretroviral</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="t3-5">
<title>Clinical and health system-related determinants of adherence to ART</title>
<p id="p-23">After adjusting for potential confounding variables using multivariable logistic regression analysis, several factors, as shown in <xref ref-type="table" rid="t5">Table 5</xref>, remained significantly associated with adherence to ART. These included both clinical and health system-related determinants. Clinically, the absence of post-pill fatigue and the lack of concern regarding pill size were positively associated with adherence. From a health system perspective, reduced financial burden, uninterrupted ART supply, and access to strong social support, whether from NGOs, government programs, or community networks, also significantly enhanced adherence.</p>
<table-wrap id="t5">
<label>Table 5</label>
<caption>
<p id="t5-p-1">
<bold>Determinants of adherence to ART among PLHIV.</bold>
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>
<bold>Variables</bold>
</th>
<th>
<bold>Categories</bold>
</th>
<th>
<bold>
<italic>n</italic> (%)</bold>
</th>
<th>
<bold>Test statistic (Bivariate)</bold>
</th>
<th>
<bold>COR (95% CI) (Multivariate)</bold>
</th>
<th>
<bold>AOR (95% CI) (Multivariate)</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">
<bold>Clinical factors</bold>
</td>
</tr>
<tr>
<td rowspan="2">Fatigue</td>
<td>Disagree</td>
<td>385 (92%)</td>
<td rowspan="2">
<italic>p</italic> = 0.024</td>
<td>0.14 (0.03–0.77)*</td>
<td>0.09 (0.02–0.37)*</td>
</tr>
<tr>
<td>Agree</td>
<td>33 (8%)</td>
<td>Ref*</td>
<td>Ref*</td>
</tr>
<tr>
<td rowspan="2">Too many pills</td>
<td>Disagree</td>
<td>369 (88%)</td>
<td rowspan="2">
<italic>p</italic> = 0.022</td>
<td>0.11 (0.02–0.65)</td>
<td>0.42 (0.12–1.51)</td>
</tr>
<tr>
<td>Agree</td>
<td>49 (12%)</td>
<td>Ref*</td>
<td>Ref*</td>
</tr>
<tr>
<td rowspan="2">Pill odour</td>
<td>Disagreed</td>
<td>388 (93%)</td>
<td rowspan="2">
<italic>p</italic> = 0.016</td>
<td>97.26 (2.32–4,075.16)</td>
<td>7.78 (0.66–91.35)</td>
</tr>
<tr>
<td>Agreed</td>
<td>30 (7%)</td>
<td>Ref*</td>
<td>Ref*</td>
</tr>
<tr>
<td rowspan="2">Pill size</td>
<td>Disagreed</td>
<td>255 (61%)</td>
<td>
<italic>p</italic> = 0.034</td>
<td>4.90 (1.12–21.22)*</td>
<td>3.71 (1.23–11.18)*</td>
</tr>
<tr>
<td>Agreed</td>
<td>163 (39%)</td>
<td />
<td>Ref*</td>
<td>Ref*</td>
</tr>
<tr>
<td rowspan="2">Auditory hallucinations</td>
<td>Disagreed</td>
<td>404 (97%)</td>
<td rowspan="2">
<italic>p</italic> = 0.015</td>
<td>0.04 (0.01–0.20) </td>
<td>0.30 (0.04–2.02)</td>
</tr>
<tr>
<td>Agreed</td>
<td>14 (3%)</td>
<td>Ref*</td>
<td>Ref*</td>
</tr>
<tr>
<td colspan="6">
<bold>Health system factors</bold>
</td>
</tr>
<tr>
<td rowspan="2">High cost of accessing ART</td>
<td>Disagreed</td>
<td>350 (84%)</td>
<td rowspan="2">
<italic>p</italic> = 0.031</td>
<td>0.22 (0.06–0.87)*</td>
<td>0.27 (0.10–0.73)*</td>
</tr>
<tr>
<td>Agreed</td>
<td>68 (16%)</td>
<td>Ref*</td>
<td>Ref*</td>
</tr>
<tr>
<td rowspan="2">Social support</td>
<td>Disagreed</td>
<td>327 (78%)</td>
<td rowspan="2">
<italic>p</italic> = 0.033</td>
<td>11.48 (1.22–108.51)*</td>
<td>6.62 (1.18–37.21)*</td>
</tr>
<tr>
<td>Agreed</td>
<td>91 (22%)</td>
<td>Ref*</td>
<td>Ref*</td>
</tr>
<tr>
<td rowspan="2">Interrupted ART supply</td>
<td>Disagreed</td>
<td>384 (92%)</td>
<td rowspan="2">
<italic>p</italic> = 0.028</td>
<td>15.88 (1.34–187.65)*</td>
<td>7.76 (1.02–59.30)*</td>
</tr>
<tr>
<td>Agreed</td>
<td>34 (8%)</td>
<td>Ref*</td>
<td>Ref*</td>
</tr>
<tr>
<td rowspan="2">High cost of treating comorbidities</td>
<td>Disagreed</td>
<td>406 (97%)</td>
<td rowspan="2">
<italic>p</italic> = 0.030</td>
<td>0.03 (0.01–0.18)</td>
<td>0.19 (0.03–1.4)</td>
</tr>
<tr>
<td>Agreed</td>
<td>12 (3%)</td>
<td>Ref*</td>
<td>Ref*</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p id="t5-fn-1">Ref*: Reference; *: significant at <italic>p</italic> &lt; 0.05; AOR (95% CI): adjusted odds ratio at 95% confidence level; COR (95% CI): crude/unadjusted odds ratio at 95% confidence level.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p id="p-24">Specifically, participants who did not experience post-pill fatigue had 91% lower odds of non-adherence compared to those who did experience fatigue (AOR = 0.09; 95% CI: 0.02–0.37). In other words, fatigue was a strong risk factor for suboptimal adherence. Similarly, individuals who reported no issues with pill size were 3.71 times more likely to adhere than those who found pill size problematic (AOR = 3.71; 95% CI: 1.23–11.18). For financial costs, participants who did not report high financial burden were 73% less likely to be non-adherent (AOR = 0.27; 95% CI: 0.10–0.73), indicating that cost is a barrier to optimal adherence. Moreover, ART supply was associated with a nearly eightfold increase in the odds of optimal adherence (AOR = 7.76; 95% CI: 1.02–59.30), the wide confidence interval for uninterrupted ART supply reflects the relatively small number of participants who experienced supply interruptions (<italic>n</italic> = 34). This estimate should therefore be interpreted with caution. Finally, strong social support was associated with a more than six-fold increase in the odds of optimal adherence (AOR = 6.62; 95% CI: 1.18–37.21). The combination of these five variables explained 16.4% of the variance in ART adherence (Nagelkerke <italic>R</italic><sup>2</sup> = 0.164). The model demonstrated good fit to the data, as indicated by a non-significant Pearson Chi-Square test (χ<sup>2</sup> = 29.51, df = 22, <italic>p</italic> = 0.131) and Deviance statistic (χ<sup>2</sup> = 24.45, df = 22, <italic>p</italic> = 0.324), suggesting that the predicted values from the model do not significantly differ from the observed values, supporting the model’s adequacy in explaining ART adherence behavior.</p>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p id="p-25">This study is one of the first to explore the relationship between clinical and health system factors and ART adherence in Northern Ghana, offering vital contextual insights. The reported adherence rate of 93%, though encouraging, falls marginally below the 95% benchmark set by UNAIDS for achieving sustained viral suppression and halting the global spread of HIV/AIDS by 2025 [<xref ref-type="bibr" rid="B24">24</xref>]. Globally, ART adherence remains inconsistent, with reported rates ranging from 49% to 100% [<xref ref-type="bibr" rid="B25">25</xref>]. The adherence level observed in this study closely mirrors findings from Nigeria (92.6%) [<xref ref-type="bibr" rid="B26">26</xref>], suggesting some consistency in ART uptake across West African contexts. A 2024 systematic review of ART adherence in sub-Saharan Africa reported that overall good adherence rates ranged from 43% to 84% across the region, with West African countries specifically showing rates between 43% and 60% [<xref ref-type="bibr" rid="B27">27</xref>]. Our observed adherence rate of 93.1% is considerably higher than the West African regional average, suggesting that ART programmes in Northern Ghana may be performing exceptionally well compared to neighbouring countries. However, it contrasts significantly with lower adherence rates reported in other parts of Ghana such as the Sunyani Municipality (75%), Ga West Municipality (44.6%), and Cape Coast Metropolis (79.5%) [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B16">16</xref>]. These discrepancies may reflect regional variations in health system capacity, socio-economic factors, and community engagement in HIV care. However, it is important to note that these are plausible hypotheses rather than empirically established explanations, as direct comparative studies across Ghanaian regions are limited. Nevertheless, previous reports from the Ghana Health Service have documented regional disparities in healthcare infrastructure, human resources for health, and funding allocations, which could contribute to differences in ART adherence outcomes [<xref ref-type="bibr" rid="B28">28</xref>]. The adherence rate observed in this study suggests that when adequately resourced and contextually adapted, ART programs in Northern Ghana can meet or approach global benchmarks. This reinforces the need to replicate and scale context-specific adherence strategies across regions with adherence which falls short of the 95% global benchmark.</p>
<p id="p-26">We also note the predominance of female participants (73.2%) in our study sample. This pattern is consistent with national HIV epidemiology in Ghana, where women bear a disproportionate burden of HIV infection. According to the Ghana AIDS Commission, HIV prevalence among females (2.14%) was approximately 2.5 times higher than that among males (0.85%) [<xref ref-type="bibr" rid="B29">29</xref>]. Beyond epidemiological factors, socio-cultural dynamics in Northern Ghana may also contribute; women tend to access antenatal and reproductive health services more frequently, creating more opportunities for HIV testing and linkage to care. Additionally, gender norms that encourage women to prioritize family health may lead to greater healthcare engagement. These combined factors likely explain the overrepresentation of women in our study sample, which reflects the real-world demographic profile of PLHIV accessing ART services in the Tamale Metropolis.</p>
<p id="p-27">Clinically, the study identified post-pill fatigue and pill size as significant barriers to adherence. While pill size is not a physiological side effect, it emerged as a perceptual barrier impacting patient motivation to maintain treatment regimens. These findings are consistent with earlier studies which highlighted how both physiological side effects and formulation-related inconveniences undermine adherence [<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B30">30</xref>–<xref ref-type="bibr" rid="B31">31</xref>]. O’Connell et al. (2022) [<xref ref-type="bibr" rid="B24">24</xref>] and other studies [<xref ref-type="bibr" rid="B32">32</xref>–<xref ref-type="bibr" rid="B34">34</xref>] noted that the emergence of side effects during ART initiation is often associated with therapy interruptions, while Loveday et al. (2022) [<xref ref-type="bibr" rid="B21">21</xref>] emphasized that any adverse effect impairing a patient’s functional capacity poses a long-term threat to adherence. These findings highlight the importance of ongoing pharmacovigilance, patient-centered drug formulation (e.g., smaller or more palatable pills), and early side effect management. Health facilities should incorporate routine screening and counseling for side effects as part of ART adherence interventions.</p>
<p id="p-28">Financial access was identified as a factor associated with adherence. Participants with reduced financial burden were 73% more likely to adhere to treatment. This aligns with findings by Loveday et al. (2022) [<xref ref-type="bibr" rid="B21">21</xref>], who emphasized the economic pressures such as employment retention and transport costs as barriers to ART adherence. These results reinforce the importance of policies that reduce out-of-pocket expenses, such as subsidized ART-related services or transport support. Financial protection mechanisms must be integrated into national HIV programs to improve long-term treatment retention.</p>
<p id="p-29">Social support was shown to significantly enhance adherence, increasing the likelihood of consistent treatment by more than sixfold. This corroborates findings from prior studies which reported that peer groups, supportive families, and stigma-free communities are strongly associated with improved adherence outcomes [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B35">35</xref>–<xref ref-type="bibr" rid="B37">37</xref>]. Conversely, social isolation or stigma can fracture critical support systems. HIV care programs must embed psychosocial interventions, including peer support groups and community sensitization campaigns into ART delivery models. Tailored support systems can buffer stigma and reinforce treatment commitment.</p>
<p id="p-30">Health system functionality, particularly uninterrupted ART supply, also proved critical. Individuals with consistent access were 7.76 times more likely to adhere, echoing studies that have reported drug stock-outs, clinic appointment delays, and occupational conflicts as major adherence barriers [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B35">35</xref>]. Strengthening ART supply chains and enhancing health facility responsiveness are non-negotiable. Integration of digital inventory tracking systems, improved staff capacity, and workplace flexibility policies for ART clients should be prioritized.</p>
<p id="p-31">Collectively, these findings carry critical implications for clinical practice, health policy, and HIV program design. They underscore the need for comprehensive, multi-level interventions that address not only the clinical dimensions of HIV care but also the socio-economic and systemic determinants of adherence. Key strategies include ensuring the consistent availability of ART, minimizing patient costs, proactively managing side effects, and fostering robust community support structures. The involvement of civil society organizations, community health workers, and policy makers will be essential in translating these findings into sustainable programmatic improvements.</p>
<sec id="t4-1">
<title>Limitations</title>
<p id="p-32">This study offers important insights into ART adherence in Northern Ghana. The high response rate and consistent data collection procedures also enhance the reliability of the findings. Nonetheless, several limitations should be acknowledged. First, the study excluded individuals in their first six months of ART initiation, those who were critically ill, co-infected with tuberculosis, or with speech and hearing impairments. As a result, some unique adherence challenges experienced by these groups may not have been captured. Future studies should broaden inclusion criteria to reflect a more diverse patient population and ensure greater inclusivity.</p>
<p id="p-33">Second, the cross-sectional nature of the study limits the ability to draw causal inferences between the identified factors and ART adherence. To better understand temporal dynamics and causal pathways, longitudinal and interventional studies are recommended. Third, although the study employed a consecutive sampling method, a non-probabilistic approach that limits generalizability, we mitigated potential selection bias by recruiting participants systematically as they presented at ART clinics. Additionally, data collection across multiple health facilities with diverse demographics helped to improve representativeness and reduce the likelihood of sampling skew. Fourth, adherence was measured by self-report. Self-reported adherence is subject to recall bias and social desirability bias. Future studies should consider objective measures such as pill counts, electronic drug monitors, or pharmacy refill records to complement self-reports. Fifth, the pretest sample for questionnaire refinement was small (<italic>n</italic> = 3), which may have limited our ability to detect all ambiguous or confusing items. Sixth, variables for the multivariable model were selected based on bivariate statistical significance (<italic>p</italic> &lt; 0.05). While this approach is common in exploratory crosssectional studies, it may have excluded variables that are clinically important but did not reach statistical significance due to limited power or small subgroup sizes. Future studies should consider alternative variable selection methods (e.g., inclusion of all a priori clinically relevant variables) to reduce the risk of residual confounding. Because of the cross-sectional design, we cannot infer causality. All reported associations reflect statistical relationships at a single point in time and should not be interpreted as causal effects. Longitudinal or interventional studies are needed to establish directionality.</p>
<p id="p-34">Despite these limitations, the study offers valuable baseline data and contextual evidence that can inform policy and programming efforts to improve ART adherence in similar low-resource settings.</p>
<p id="p-35">In conclusion, this study identified a 93% ART adherence rate among PLHIV which falls short of the 95% global benchmark. Clinical factors promoting adherence included the absence of fatigue and concerns related to pill size, while health system related factors promoting adherence included reduced cost of access, consistent ART supply, and good social support. The Ghana AIDS Commission and its implementing partners are urged to strengthen community-based social support networks, expand ART distribution points, and develop targeted educational initiatives to improve therapy adherence and contribute to achieving epidemic control.</p>
</sec>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AIDS</term>
<def>
<p>Acquired Immunodeficiency Syndrome</p>
</def>
</def-item>
<def-item>
<term>ART</term>
<def>
<p>Antiretroviral Therapy</p>
</def>
</def-item>
<def-item>
<term>HIV</term>
<def>
<p>Human Immunodeficiency Virus</p>
</def>
</def-item>
<def-item>
<term>NRTI</term>
<def>
<p>nucleoside reverse transcriptase inhibitor</p>
</def>
</def-item>
<def-item>
<term>NtRTI</term>
<def>
<p>nucleotide reverse transcriptase inhibitor</p>
</def>
</def-item>
<def-item>
<term>PLHIV</term>
<def>
<p>persons living with Human Immunodeficiency Virus</p>
</def>
</def-item>
<def-item>
<term>TCH</term>
<def>
<p>Tamale Central Hospital</p>
</def>
</def-item>
<def-item>
<term>TTH</term>
<def>
<p>Tamale Teaching Hospital</p>
</def>
</def-item>
<def-item>
<term>TWH</term>
<def>
<p>Tamale West Hospital</p>
</def>
</def-item>
</def-list>
</glossary>
<sec id="s5">
<title>Declarations</title>
<sec id="t-5-1">
<title>Acknowledgments</title>
<p>The authors thank the study participants for their time and the hospital workers and management of the ART/STI clinic for their support.</p>
</sec>
<sec id="t-5-2">
<title>Author contributions</title>
<p>FGAS: Conceptualization, Methodology, Formal analysis, Data curation, Investigation, Writing—original draft, Writing—review &amp; editing. UH: Conceptualization, Methodology, Validation, Writing—review &amp; editing. AA: Writing—review &amp; editing. GAA: Conceptualization, Methodology, Validation, Writing—review &amp; editing. All authors read and approved the submitted version.</p>
</sec>
<sec id="t-5-3" sec-type="COI-statement">
<title>Conflicts of interest</title>
<p>The authors have reported no conflicts of interest.</p>
</sec>
<sec id="t-5-4">
<title>Ethical approval</title>
<p>Ethics committees at the Tamale Teaching Hospital (reference TTHERC/20/11/23/01) and Ghana Health Service (GHS-ERC:053/09/23) provided ethics approval, respectively. The study was conducted in accordance with the principles of the Declaration of Helsinki.</p>
</sec>
<sec id="t-5-5">
<title>Consent to participate</title>
<p>Every participant in the study provided written, informed consent.</p>
</sec>
<sec id="t-5-6">
<title>Consent to publication</title>
<p>Not applicable.</p>
</sec>
<sec id="t-5-7" sec-type="data-availability">
<title>Availability of data and materials</title>
<p>Upon a reasonable request, the corresponding author can supply the data sets used in the current work.</p>
</sec>
<sec id="t-5-8">
<title>Funding</title>
<p>This work was conducted without external funding.</p>
</sec>
<sec id="t-5-9">
<title>Copyright</title>
<p>© The Author(s) 2026.</p>
</sec>
</sec>
<sec id="s6">
<title>Publisher’s note</title>
<p>Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.</p>
</sec>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tseng</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Seet</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future</article-title>
<source>Br J Clin Pharmacol</source>
<year iso-8601-date="2015">2015</year>
<volume>79</volume>
<fpage>182</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1111/bcp.12403</pub-id>
<pub-id pub-id-type="pmid">24730660</pub-id>
<pub-id pub-id-type="pmcid">PMC4309625</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orlando</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Silaghi</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Cicala</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lowole</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Massango</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lunghi</surname>
<given-names>R</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>The global response to HIV/AIDS in sub-Saharan Africa: achievements, challenges, and perspectives for the future</article-title>
<source>Front Public Health</source>
<year iso-8601-date="2025">2025</year>
<volume>13</volume>
<elocation-id>1665666</elocation-id>
<pub-id pub-id-type="doi">10.3389/fpubh.2025.1665666</pub-id>
<pub-id pub-id-type="pmid">41246083</pub-id>
<pub-id pub-id-type="pmcid">PMC12615466</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bekker</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Alleyne</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baral</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cepeda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Daskalakis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dowdy</surname>
<given-names>D</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission</article-title>
<source>Lancet</source>
<year iso-8601-date="2018">2018</year>
<volume>392</volume>
<fpage>312</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1016/s0140-6736(18)31070-5</pub-id>
<pub-id pub-id-type="pmid">30032975</pub-id>
<pub-id pub-id-type="pmcid">PMC6323648</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moyo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Moyo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Murewanhema</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mhango</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chitungo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dzinamarira</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Key populations and Sub-Saharan Africa's HIV response</article-title>
<source>Front Public Health</source>
<year iso-8601-date="2023">2023</year>
<volume>11</volume>
<elocation-id>1079990</elocation-id>
<pub-id pub-id-type="doi">10.3389/fpubh.2023.1079990</pub-id>
<pub-id pub-id-type="pmid">37261232</pub-id>
<pub-id pub-id-type="pmcid">PMC10229049</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="web">
<article-title>UNAIDS. UNAIDS fact sheet 2022 [Internet]</article-title>
<comment>Geneva: UNAIDS; Retrieved January 29, 2026. Available from: <uri xlink:href="https://www.unaids.org/sites/default/files/media_asset/data-book-2022_en.pdf">https://www.unaids.org/sites/default/files/media_asset/data-book-2022_en.pdf</uri></comment>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prah</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hayfron-Benjamin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Abdulai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lasim</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Nartey</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Obiri-Yeboah</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Factors Affecting Adherence to Antiretroviral Therapy among HIV/AIDS Patients in Cape Coast Metropolis, Ghana</article-title>
<source>J HIV AIDS</source>
<year iso-8601-date="2018">2018</year>
<volume>4</volume>
<pub-id pub-id-type="doi">10.16966/2380-5536.149</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heestermans</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Browne</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Aitken</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Vervoort</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Klipstein-Grobusch</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review</article-title>
<source>BMJ Glob Health</source>
<year iso-8601-date="2016">2016</year>
<volume>1</volume>
<elocation-id>e000125</elocation-id>
<pub-id pub-id-type="doi">10.1136/bmjgh-2016-000125</pub-id>
<pub-id pub-id-type="pmid">28588979</pub-id>
<pub-id pub-id-type="pmcid">PMC5321378</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Addo</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Aboagye</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Tarkang</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>Factors influencing adherence to antiretroviral therapy among HIV/AIDS patients in the Ga West Municipality, Ghana</article-title>
<source>IJID Reg</source>
<year iso-8601-date="2022">2022</year>
<volume>3</volume>
<fpage>218</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijregi.2022.04.009</pub-id>
<pub-id pub-id-type="pmid">35755462</pub-id>
<pub-id pub-id-type="pmcid">PMC9216268</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tuot</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sim</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Nagashima-Hayashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chhoun</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Teo</surname>
<given-names>AKJ</given-names>
</name>
<name>
<surname>Prem</surname>
<given-names>K</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>What are the determinants of antiretroviral therapy adherence among stable people living with HIV? A cross-sectional study in Cambodia</article-title>
<source>AIDS Res Ther</source>
<year iso-8601-date="2023">2023</year>
<volume>20</volume>
<elocation-id>47</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12981-023-00544-w</pub-id>
<pub-id pub-id-type="pmid">37452342</pub-id>
<pub-id pub-id-type="pmcid">PMC10347818</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Deonandan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krentel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oladimeji</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Yaya</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Prevalence and factors associated with HIV treatment non-adherence among people living with HIV in three regions of Cameroon: A cross-sectional study</article-title>
<source>PLOS ONE</source>
<year iso-8601-date="2023">2023</year>
<volume>18</volume>
<elocation-id>e0283991</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0283991</pub-id>
<pub-id pub-id-type="pmid">37014900</pub-id>
<pub-id pub-id-type="pmcid">PMC10072448</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdulai</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Mevissen</surname>
<given-names>FEF</given-names>
</name>
<name>
<surname>Ruiter</surname>
<given-names>RAC</given-names>
</name>
<name>
<surname>Owusu‐Agyei</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Asante</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Bos</surname>
<given-names>AER</given-names>
</name>
</person-group>
<article-title>A qualitative analysis of factors influencing antiretroviral adherence among persons living with HIV in Ghana</article-title>
<source>J Community Appl Soc Psychol</source>
<year iso-8601-date="2021">2021</year>
<volume>32</volume>
<fpage>135</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1002/casp.2551</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarkang</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Manu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Aku</surname>
<given-names>FY</given-names>
</name>
<name>
<surname>Anaman-Torgbor</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Khuzwayo</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Sociodemographic and health systems determinants of antiretroviral therapy adherence among human immunodeficiency virus-positive patients in the Volta Region of Ghana: A multi-centre study</article-title>
<source>SAGE Open Med</source>
<year iso-8601-date="2024">2024</year>
<volume>12</volume>
<elocation-id>20503121241229056</elocation-id>
<pub-id pub-id-type="doi">10.1177/20503121241229056</pub-id>
<pub-id pub-id-type="pmid">38357401</pub-id>
<pub-id pub-id-type="pmcid">PMC10865934</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="web">
<article-title>Consolidated guidelines for HIV care in Ghana [Internet]</article-title>
<comment>Ghana Health Service; [cited 2026 Jan 29]. Available from: <uri xlink:href="https://hivpreventioncoalition.unaids.org/en/resources/consolidated-guidelines-hiv-care-ghana-0">https://hivpreventioncoalition.unaids.org/en/resources/consolidated-guidelines-hiv-care-ghana-0</uri></comment>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="web">
<article-title>Country progress report - Ghana Global AIDS Monitoring 2019 [Internet]</article-title>
<comment>UNAIDS; [cited 2026 Jan 29]. Available from: <uri xlink:href="https://www.unaids.org/sites/default/files/country/documents/GHA_2019_countryreport.pdf">https://www.unaids.org/sites/default/files/country/documents/GHA_2019_countryreport.pdf</uri></comment>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="book">
<source>Ghana AIDS Commission</source>
<comment>2020 HIV and AIDS Estimates and Projections. Ghana AIDS Commission; 2020.</comment>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abubakari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Issah</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mutaka</surname>
<given-names>MAO</given-names>
</name>
<name>
<surname>Asumah</surname>
<given-names>MN</given-names>
</name>
</person-group>
<article-title>Determinants of Virological Failure in HIV Patients on Highly Active Antiretroviral Therapy (HAART): A Retrospective Cross-Sectional Study in the Upper East Region of Ghana</article-title>
<source>Venereology</source>
<year iso-8601-date="2023">2023</year>
<volume>2</volume>
<fpage>16</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.3390/venereology2010002</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atanuriba</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Apiribu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dzomeku</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Amooba</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Boamah</surname>
<given-names>Mensah AB</given-names>
</name>
<name>
<surname>Afaya</surname>
<given-names>RA</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>“Some believe those who say they can cure it” perceived barriers to antiretroviral therapy for children living with HIV/AIDS: Qualitative exploration of caregivers experiences in tamale metropolis</article-title>
<source>PLOS ONE</source>
<year iso-8601-date="2022">2022</year>
<volume>17</volume>
<elocation-id>e0275529</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0275529</pub-id>
<pub-id pub-id-type="pmid">36194615</pub-id>
<pub-id pub-id-type="pmcid">PMC9531795</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Cochran</surname>
<given-names>WG</given-names>
</name>
</person-group>
<source>Sampling Techniques</source>
<edition>3rd ed</edition>
<publisher-loc>New York</publisher-loc>
<publisher-name>John Wiley &amp; Sons</publisher-name>
<year iso-8601-date="1991">1991</year>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Simelane</surname>
<given-names>TP</given-names>
</name>
</person-group>
<source>Socio-demographic factors affecting adherence to antiretroviral therapy in a wellness centre in South Africa [dissertation]</source>
<publisher-loc>Potchefstroom</publisher-loc>
<publisher-name>North-West University (South Africa)</publisher-name>
<year iso-8601-date="2019">2019</year>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Safira</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lubis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fahdhy</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Factors Affecting Adherence to Antiretroviral Therapy</article-title>
<source>KnE Life Sci</source>
<year iso-8601-date="2018">2018</year>
<volume>4</volume>
<elocation-id>60</elocation-id>
<pub-id pub-id-type="doi">10.18502/kls.v4i4.2264</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loveday</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Furin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hlangu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Naidoo</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>“I am alive because of her”: factors affecting adherence to combination antiretroviral therapy among people living with HIV in KwaZulu-Natal, South Africa</article-title>
<source>BMC Infect Dis</source>
<year iso-8601-date="2022">2022</year>
<volume>22</volume>
<elocation-id>680</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12879-022-07667-x</pub-id>
<pub-id pub-id-type="pmid">35941552</pub-id>
<pub-id pub-id-type="pmcid">PMC9361592</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Opara</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Iheanacho</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Nebo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ingwu</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Anetekhai</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Anarado</surname>
<given-names>AN</given-names>
</name>
</person-group>
<article-title>Factors affecting adherence to anti-retroviral therapy among women attending HIV clinic of a tertiary health institution in SouthEastern, Nigeria</article-title>
<source>Afr Health Sci</source>
<year iso-8601-date="2022">2022</year>
<volume>22</volume>
<fpage>456</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.4314/ahs.v22i1.54</pub-id>
<pub-id pub-id-type="pmid">36032451</pub-id>
<pub-id pub-id-type="pmcid">PMC9382475</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aduloju</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Psychosocial Factors Affecting Adherence to Antiretroviral Therapy among Persons Living with HIV/AIDS in Ekiti State: A Multicentre Study</article-title>
<source>Niger Stethosc</source>
<year iso-8601-date="2023">2023</year>
<volume>5</volume>
<fpage>26</fpage>
<lpage>34</lpage>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Connell</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Sherani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kisteneff</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Slater</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>CF</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Factors Affecting Adherence With Follow-up Appointments in HIV Patients</article-title>
<source>Cureus</source>
<year iso-8601-date="2022">2022</year>
<volume>14</volume>
<elocation-id>e29424</elocation-id>
<pub-id pub-id-type="doi">10.7759/cureus.29424</pub-id>
<pub-id pub-id-type="pmid">36299938</pub-id>
<pub-id pub-id-type="pmcid">PMC9586838</pub-id>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="web">
<article-title>Status and challenges of ART adherence in SA: How the UN can help [Internet]</article-title>
<comment>World Health Organization Regional Office for Africa; [cited 2026 Jan 29]. Available from: <uri xlink:href="https://www.afro.who.int/countries/south-africa/news/status-and-challenges-art-adherence-sa-how-un-can-help">https://www.afro.who.int/countries/south-africa/news/status-and-challenges-art-adherence-sa-how-un-can-help</uri></comment>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anyaike</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Atoyebi</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Musa</surname>
<given-names>OI</given-names>
</name>
<name>
<surname>Bolarinwa</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Durowade</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Ogundiran</surname>
<given-names>A</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Adherence to combined Antiretroviral therapy (cART) among people living with HIV/AIDS in a Tertiary Hospital in Ilorin, Nigeria</article-title>
<source>Pan Afr Med J</source>
<year iso-8601-date="2019">2019</year>
<volume>32</volume>
<elocation-id>10</elocation-id>
<pub-id pub-id-type="doi">10.11604/pamj.2019.32.10.7508</pub-id>
<pub-id pub-id-type="pmid">31080546</pub-id>
<pub-id pub-id-type="pmcid">PMC6497984</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almeida</surname>
<given-names>PRS</given-names>
</name>
<name>
<surname>Rafael</surname>
<given-names>CAC</given-names>
</name>
<name>
<surname>Pimentel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Abecasis</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Sebastião</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Morais</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Adherence to antiretroviral therapy among HIV-1 patients from sub-Saharan Africa: a systematic review</article-title>
<source>Aids Rev</source>
<year iso-8601-date="2024">2024</year>
<volume>26</volume>
<fpage>102</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.24875/aidsrev.24000004</pub-id>
<pub-id pub-id-type="pmid">39466708</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="web">
<article-title>Ghana Harmonized Health Facility Assessment 2022-2023: National report [Internet]</article-title>
<comment>Ghana: Ministry of Health; [cited 2026 Jan 29]. Available from: <uri xlink:href="https://data-archive.hhfa.online/index.php/catalog/143">https://data-archive.hhfa.online/index.php/catalog/143</uri></comment>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="web">
<article-title>National and sub-national HIV and AIDS estimates and projections: 2024 report [Internet]</article-title>
<comment>Accra: Ghana AIDS Commission; [cited 2026 Jan 29]. Available from: <uri xlink:href="https://www.ghanet.net/assets/pdf/docs/GAC%20Estimate%20Report%202024.pdf">https://www.ghanet.net/assets/pdf/docs/GAC%20Estimate%20Report%202024.pdf</uri></comment>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eze</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Sulaiman</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mat</surname>
<given-names>Daud Z'</given-names>
</name>
<name>
<surname>Babadoko</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Association Between Belief in Medicine and Adherence to Antiretroviral Therapy Among Human Immunodeficiency Virus Adults in Zaira, Kaduna State, Nigeria</article-title>
<source>Cureus</source>
<year iso-8601-date="2023">2023</year>
<volume>15</volume>
<elocation-id>e36489</elocation-id>
<pub-id pub-id-type="doi">10.7759/cureus.36489</pub-id>
<pub-id pub-id-type="pmid">37090307</pub-id>
<pub-id pub-id-type="pmcid">PMC10118400</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalungwe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mbalinda</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Karonga</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Simwanza</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Mumba</surname>
<given-names>Mtambo CM</given-names>
</name>
<name>
<surname>Nyashanu</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Exploring barriers to antiretroviral therapy adherence among pregnant women: A scoping literature review</article-title>
<source>Int J Gynecol Obstet</source>
<year iso-8601-date="2022">2022</year>
<volume>159</volume>
<fpage>343</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1002/ijgo.14130</pub-id>
<pub-id pub-id-type="pmid">35122429</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adeniyi</surname>
<given-names>OV</given-names>
</name>
<name>
<surname>Ajayi</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Ter</surname>
<given-names>Goon D</given-names>
</name>
<name>
<surname>Owolabi</surname>
<given-names>EO</given-names>
</name>
<name>
<surname>Eboh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Factors affecting adherence to antiretroviral therapy among pregnant women in the Eastern Cape, South Africa</article-title>
<source>BMC Infect Dis</source>
<year iso-8601-date="2018">2018</year>
<volume>18</volume>
<elocation-id>175</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12879-018-3087-8</pub-id>
<pub-id pub-id-type="pmid">29653510</pub-id>
<pub-id pub-id-type="pmcid">PMC5899366</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ejigu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Desalegn</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Mulatu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mosisa</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Adherence to Combined Antiretroviral Therapy and Associated Factors Among People Living with HIV Attending Nekemte Specialized Hospital, Oromia, Ethiopia: A Cross-Sectional Study</article-title>
<source>HIV/AIDS - Res Palliat Care</source>
<year iso-8601-date="2020">2020</year>
<volume>12</volume>
<fpage>97</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.2147/hiv.s239995</pub-id>
<pub-id pub-id-type="pmid">32210636</pub-id>
<pub-id pub-id-type="pmcid">PMC7071940</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ankomah</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ganle</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Lartey</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Kwara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nortey</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Okyerefo</surname>
<given-names>MP</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>ART access-related barriers faced by HIV-positive persons linked to care in southern Ghana: a mixed method study</article-title>
<source>BMC Infect Dis</source>
<year iso-8601-date="2016">2016</year>
<volume>16</volume>
<elocation-id>738</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12879-016-2075-0</pub-id>
<pub-id pub-id-type="pmid">27927183</pub-id>
<pub-id pub-id-type="pmcid">PMC5142337</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Yusuf</surname>
<given-names>AB</given-names>
</name>
</person-group>
<source>Adherence to ART among HIV infected female sex workers in Nigeria [dissertation]</source>
<publisher-loc>Minneapolis (MN)</publisher-loc>
<publisher-name>Walden University</publisher-name>
<year iso-8601-date="2019">2019</year>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chime</surname>
<given-names>OH</given-names>
</name>
<name>
<surname>Arinze-Onyia</surname>
<given-names>SU</given-names>
</name>
<name>
<surname>Obionu</surname>
<given-names>CN</given-names>
</name>
</person-group>
<article-title>Do peer support groups have an effect on medication adherence? A study among people living with HIV/AIDS in Enugu State, Nigeria</article-title>
<source>Proc Singap Healthc</source>
<year iso-8601-date="2018">2018</year>
<volume>27</volume>
<fpage>256</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1177/2010105818760923</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sánchez</surname>
<given-names>Peña S</given-names>
</name>
<name>
<surname>Pastor</surname>
<given-names>Bravo MDM</given-names>
</name>
<name>
<surname>Cánovas</surname>
<given-names>Tomás MÁ</given-names>
</name>
<name>
<surname>Almansa-Martínez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Peñalver</surname>
<given-names>Guillen C</given-names>
</name>
<name>
<surname>Jiménez-Ruiz</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Factores relacionados con la adherencia al tratamiento antirretroviral en mujeres con VIH: Un estudio mixto con diseño secuencial</article-title>
<source>Enferm Glob</source>
<year iso-8601-date="2021">2021</year>
<volume>20</volume>
<fpage>1</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.6018/eglobal.437711</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>